Home
Katrin Kleinmanns's picture
Photo:
Spiros Kotopoulis

Katrin Kleinmanns

Guest Researcher
  • E-mailkatrin.kleinmanns@uib.no
  • Phone96703136
  • Visitor Address
    Jonas Lies veg 87
    Laboratory building 9th floor
    5021 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Katrin´s research focuses on the development of immunocompetent patient-derived xenograft (PDX) models of ovarian carcinomas to improve therapeutic interventions through novel immune therapies and targeted fluorescence image-guided surgery. These advanced mouse models are additionally reconstituted with a functional human immune system, which replicate the heterogeneities observed in patient tumours whilst also reproducing key features of the human immune system. Immunotherapies, neither immune-checkpoint inhibitor nor chimeric antigen receptor (CAR) T cells, have been shown successful in ovarian carcinomas, yet. Key drivers for her project are the genomic and phenotypic characterization of her established PDX models including the verification of the genomic fidelity to the paired primary tumors as well as the phenotypic deciphering of the complex tumor microenvironment (TME). The aim of Katrin´s project is to provide a good and reliable preclinical animal model that combines the interactions of the TME, including human immune system and genomic evolution of tumor cells.

Kleinmanns, K. et al. (2022). Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. In: Akslen, L.A., Watnick, R.S. (eds) Biomarkers of the Tumor Microenvironment. Springer, Cham. https://doi.org/10.1007/978-3-030-98950-7_19

Perrone, M.G.; Vitale, P.; Miciaccia, M.; Ferorelli, S.; Centonze, A.; Solidoro, R.; Munzone, C.; Bonaccorso, C.; Fortuna, C.G.; Kleinmanns, K.; Bjørge, L.; Scilimati, A. Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. Pharmaceuticals 2022, 15, 668. https://doi.org/10.3390/ph15060668

Kleinmanns, K.; Gullaksen, S.-E.; Bredholt, G.; Davidson, B.; Torkildsen, C.F.; Grindheim, S.; Bjørge, L.; McCormack, E. Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. Cancers 2022, 14, 3092. doi.org/10.3390/cancers14133092

García de Jalón, E., Kleinmanns, K., Fosse, V. et al. Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. Mol Imaging Biol 25, 144–155 (2021). https://doi.org/10.1007/s11307-021-01685-y

Popa, M., Fosse, V., Kleinmanns, K., Bjørge, L., McCormack, E. (2021). Xenograft Models of Ovarian Cancer for Therapy Evaluation. In: Kreeger, P.K. (eds) Ovarian Cancer. Methods in Molecular Biology, vol 2424. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1956-8_18

Anandan, S.; Thomsen, L.C.V.; Gullaksen, S.-E.; Abdelaal, T.; Kleinmanns, K.; Skavland, J.; Bredholt, G.; Gjertsen, B.T.; McCormack, E.; Bjørge, L. Phenotypic characterization by mass cytometry of the microenvironment in ovarian cancer and impact of tumor dissociation methods. Cancers 2021, 13, 755.

Kleinmanns, K., et al., The Emerging Role of CD24 in Cancer Theranostics—A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond. Journal of Personalized Medicine, 2020. 10(4): p. 255.

Kleinmanns, K., et al., CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine, 2020. 56: p. 102783.

Kleinmanns, K., et al., CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine, 2020. 56: p. 102782.

  • Show author(s) (2024). Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16. Journal for ImmunoTherapy of Cancer (JITC).
  • Show author(s) (2023). Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study. Cancers. 22 pages.
  • Show author(s) (2022). Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. 16 pages.
  • Show author(s) (2022). Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. Cancers. 20 pages.
  • Show author(s) (2022). Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. Pharmaceuticals.
  • Show author(s) (2022). Establishment of peritoneal dECM scaffolds for culture of ovarian cancer organoids.
  • Show author(s) (2022). Establishment of peritoneal dECM scaffolds for 3D culture of ovarian cancer organoids.
  • Show author(s) (2022). Establishment of ovarian cancer organoids on peritoneal dECM scaffolds.
  • Show author(s) (2021). Xenograft Models of Ovarian Cancer for Therapy Evaluation. . In:
    • Show author(s) (2021). Ovarian Cancer Methods and Protocols. Springer Nature.
  • Show author(s) (2021). Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers. 1-18.
  • Show author(s) (2021). Establishment of ovarian cancer organoids on peritoneal dECM scaffolds.
  • Show author(s) (2021). Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. Molecular Imaging and Biology. 144-155.
  • Show author(s) (2020). The emerging role of cd24 in cancer theranostics—a novel target for fluorescence image-guided surgery in ovarian cancer and beyond. Journal of Personalized Medicine. 1-18.
  • Show author(s) (2020). CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model . EBioMedicine. 1-12.
  • Show author(s) (2020). CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 1-13.
  • Show author(s) (2019). rethinking high-grade serous ovarian carcinoma: development of new preclinical animal models for evaluation of image-guided surgery and immunotherapy.
  • Show author(s) (2019). EP889 improved cytoreduction of ovarian cancer using CD24 targeted fluorescence image guided surgery in a preclinical murine model.
  • Show author(s) (2017). Engraftement optimization, charaterization and tumor spread tracking by preclinical imaging in ovarian cancer patiant.

More information in national current research information system (CRIStin)